First Evidence of Omega-3 EPA/DHA Effect on a Potential Root Cause of Dry Eye Syndrome Presented at the Cornea Society/EBAA Fall Educational Symposium



ORLANDO, Fla., Nov. 2, 2011 /CNW/ -- Dr. Gregory Smith, world-renowned ophthalmologist and Attending Surgeon at the famed Wills Eye Hospital in Philadelphia, presented new study data at the Cornea Society/EBAA Fall Educational Symposium that would significantly enhance the way Dry Eye symptoms are treated. Smith's abstract, entitled "Penetration of rTG omega-3 into the meibomian glands after oral administration" provided the first evidence that omega-3 EPA/DHA can penetrate the meibomian gland and change the oil in the meibum, which contributes to the lipid layer of the tear.

Using PRN Physician Recommended Nutriceuticals' Dry Eye Omega Benefits, Smith conducted a pilot study in 20 patients to assess red blood cell saturation of EPA and DHA using an omega-3 index test and meibomian gland secretion samples. Eighty-two percent of patients treated with PRN Dry Eye Omega Benefits showed EPA and DHA present in the meibum after eight weeks of treatment (compared to 0% at baseline) along with significant elevation of the omega-3 index. Additionally, 70% of patients became asymptomatic during that time, with 100% noting a decrease in their main complaint. Improvement in tear breakup time was statistically significant and all patients with corneal staining at baseline significantly improved.

Smith's presentation was attended by over 100 of leading ophthalmologists, partly due to the pivotal nature of the study. Intrigued by the findings, one attendee asked if Smith typically administers Dry Eye Omega Benefits as monotherapy to his Dry Eye patients, to which Smith replied, "Yes, and I have achieved a 70% long-term benefit." Following the presentation, Smith said that he was "gratified with the promising study results. The expanded study already underway will offer additional validation for the treatment impact of these findings."

PRN sees these findings as a tremendous opportunity to promote the unique value of its Dry Eye Omega Benefits product. As Dr. Michael Gross, Chief Medical Officer for PRN stated, "As the first product proven to penetrate the meibum, we believe these paradigm-changing findings validate the use of Dry Eye Omega Benefits because of its significantly greater bioavailability as a triglyceride form omega-3 EPA and DHA, its unique formulation and its obvious potential in addressing a potential root cause of dry eye symptoms."


    About PRN Physician Recommended Nutriceuticals


PRN is a leading developer of specialty omega-3 products and nutritional supplements. Developed by doctors and recommended by world-renowned medical thought leaders, PRN's products are supported by medical evidence and are unmatched in quality and purity.


    About PRN Dry Eye Omega Benefits


A solution for those suffering with dry, scratchy, red, or irritated eyes, Dry Eye Omega Benefits is a custom formulation with a high concentration of Omega-3 EPA/DHA in its natural triglyceride form, combined with vitamin D3 for additional comprehensive health benefits. The product, launched in 2007, has a patent pending for its potential adjuvant use in meibomian gland dysfunction.



SOURCE PRN Physician Recommended Nutriceuticals

For further information: Michael B. Gross, MD, Chief Medical Officer, +1-610-862-0182

Profil de l'entreprise

PRN Physician Recommended Nutriceuticals

Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.